Shineco Pharma(02096.HK)Net profit growth of 86.2% to 1.344 billion yuan in 2025, final dividend of 0.18 yuan

NightAirdropper · 2026-03-25T15:52:32+00:00

Sensorium Pharmaceuticals announced its 2025 annual results, with revenue of 7.731 billion yuan, a year-over-year increase of 16.5%. Of this, revenue from innovative medicines grew 27.9% to 6.304 billion yuan, with notable performance in the neuroscience and anti-tumor fields. Net profit attributable to shareholders reached 1.344 billion yuan, an increase of 86.2%. The board declared a dividend of 0.18 yuan per share.

NightAirdropper

2026-03-25 15:52:32

Abstract generation in progress

Gelonghui, March 25 — Sinopharm Group (02096.HK) announced its annual results for the year ending December 31, 2025. The group’s revenue reached RMB 7.731 billion, a 16.5% increase year-over-year. Of this, innovative drug business revenue was RMB 6.304 billion, accounting for 81.5% of total revenue, up 27.9% year-over-year. Net profit attributable to shareholders was RMB 1.344 billion, an increase of RMB 622 million from RMB 722 million in 2024, up 86.2%. Adjusted profit attributable to shareholders was RMB 1.280 billion, up RMB 273 million from RMB 1.007 billion in 2024, a 27.1% increase.

The group’s revenue mainly comes from focused therapeutic areas. Neuroscience revenue was RMB 2.753 billion, accounting for 35.6% of total revenue, up 26.6% from RMB 2.174 billion in 2024; autoimmune disease revenue was RMB 1.892 billion, representing 24.5% of total revenue, up 4.5% from RMB 1.811 billion in 2024; oncology revenue was RMB 1.987 billion, making up 25.7% of total revenue, a 53.0% increase from RMB 1.298 billion in 2024; other areas generated RMB 1.099 billion, accounting for 14.2% of total revenue, down 18.7% from RMB 1.352 billion in 2024.

The board of directors declared a final dividend of RMB 0.18 per share for the year ending December 31, 2025, payable to shareholders on June 24, 2026 (Wednesday), whose names appear on the company’s shareholder register.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.